On April 17, 2026 Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, reported expansion cohort data from the Phase 1/2 study of JK06, a 5T4-targeted antibody drug conjugate (ADC), in patients with unresectable locally advanced or metastatic cancer, including non-small cell lung cancer (NSCLC) and breast cancer, which is being presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 on April 17-22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"JK06 continues to demonstrate encouraging and durable efficacy among heavily pre-treated metastatic solid tumors. Partial responses have now been observed across four different cancers, including NSCLC and breast cancer, at multiple dose levels. These data are complemented by a consistently favorable safety profile, underscoring our belief that JK06 has the potential to be an important new first-in-class ADC that can address the unmet needs of patients with 5T4-expressing cancers," said Sam Murphy, Chief Executive Officer of Salubris Biotherapeutics. "These results provide a robust foundation for further exploration of JK06 in NSCLC and breast cancer and will propel our efforts to interrogate the pan-tumor opportunity. We look forward to progressing this study into the next stages of expansion cohorts, including additional monotherapy cohorts and evaluation of JK06 in multiple combination therapy regimens."

Expansion cohort data presented at AACR (Free AACR Whitepaper) include 112 patients enrolled in Europe with advanced relapsed/refractory solid tumors who were treated with JK06 once every three weeks, including two randomized dose cohorts (3.7 mg/kg, 4.5 mg/kg) in NSCLC and breast cancer and a basket cohort consisting of multiple tumor types known to express 5T4. The data cutoff was March 29, 2026.

Key efficacy findings include:

Among 38 response-evaluable NSCLC patients, 10 attained confirmed PRs (ORR 26%), including three out of seven response-evaluable squamous cell NSCLC patients (ORR 43%), and two of three response-evaluable Epidermal Growth Factor Receptor (EGFR) mutant patients.
Five out of 19 response-evaluable breast cancer patients attained PRs (ORR 26%), including four out of nine hormone receptor-positive (HR+) breast cancer patients (ORR 44%).
Among other tumor types, the first and only response-evaluable gastric cancer patient enrolled attained a partial response (PR, -55%), and one of four response-evaluable cervical cancer patients attained a partial response (PR, -49%).
Among 112 safety-evaluable patients enrolled in expansion cohorts, key safety findings include:

Treatment with JK06 at doses ≤ 5.2 mg/kg was generally well-tolerated with predominantly low grade (Grades 1 and 2) treatment-related adverse events (TRAEs) and manageable toxicities.
All JK06-related AEs of any grade are below 10% frequency overall except for asthenia (11% overall).
Only three total Grade 3 events have been observed to date among the 112 patients (fatigue, gait disturbance, keratitis), and no Grade 4 or 5 events have been observed.
Of the total 153 patients enrolled across all dose levels in dose escalation and expansion, only seven patients have dose-reduced due to a TRAE resulting from JK06.

The Phase 1/2 open-label, dose-escalation and expansion study (NCT06667960) to assess the safety, pharmacokinetics, and preliminary efficacy of JK06 is ongoing.

Details of the AACR (Free AACR Whitepaper) presentation are as follows:

Title: A Phase 1/2 Study of JK06, a 5T4-Targeted Antibody Drug Conjugate (ADC), In Patients with Unresectable Locally Advanced or Metastatic Cancer
Presenter: Omar Saavedra, M.D., Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Abstract #: CT250
Session: Phase II Clinical Trials
Date/Time: April 21, 2026 | 2:00 – 5:00 PM PT

About JK06

JK06 is a first-in-class quadrivalent, biparatopic ADC that selectively targets 5T4 with a monomethyl auristatin E (MMAE) payload. 5T4 is an oncofetal protein that is overexpressed in a wide range of solid tumors, including non-small cell lung cancer (NSCLC), breast, gastric and genitourinary cancers, and is associated with more aggressive tumor progression and reduced survival. JK06 has demonstrated picomolar affinity for 5T4 and enhanced internalization resulting from the biparatopic design. Together with stable, site-specific payload conjugation, JK06 has demonstrated the potential for robust efficacy and a favorable safety profile.

(Press release, Salubris Biotherapeutics, APR 17, 2026, View Source [SID1234664553])

On April 17, 2026 Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, reported the closing of its concurrent upsized public offerings of 12,147,887 shares of its common stock at a public offering price of $142.00 per share and $500.0 million aggregate principal amount of 0.50% convertible senior notes due 2033 (the "notes"). The shares of common stock issued and sold in the common stock offering include 1,584,506 shares issued upon exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offerings, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, were approximately $2,225.0 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan, TD Cowen and Guggenheim Securities acted as book-running managers for the note offering and the common stock offering. LifeSci Capital acted as lead manager for the note offering and the common stock offering.

The notes are senior, unsecured obligations of Revolution Medicines and will accrue interest at a rate of 0.50% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, beginning on November 1, 2026. The notes will mature on May 1, 2033, unless earlier repurchased, redeemed or converted. Before February 1, 2033, noteholders will have the right to convert their notes only upon the occurrence of certain events. From, and including, February 1, 2033, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Revolution Medicines will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Revolution Medicines’ election. The initial conversion rate is 5.0302 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $198.80 per share of common stock. The initial conversion price represents a premium of approximately 40.0% over the public offering price per share of common stock in the common stock offering. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Revolution Medicines’ option at any time, and from time to time, on or after May 6, 2030 and on or before the 31st scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Revolution Medicines’ common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

If a "fundamental change" (as defined in the indenture for the notes) occurs, then, subject to a limited exception, noteholders may require Revolution Medicines to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.

Revolution Medicines estimates that the aggregate net proceeds from the offerings were approximately $2,137.2 million, after deducting the underwriting discounts and commissions and estimated offering expenses. Revolution Medicines intends to use the net proceeds from the offerings for general corporate purposes, including research and development expenses, expenses relating to the potential commercialization of one or more of its product candidates, general and administrative expenses and capital expenditures.

The offerings were made pursuant to an effective shelf registration statement on file with the Securities and Exchange Commission (the "SEC"). Each offering was made only by means of a prospectus supplement relating to that offering and an accompanying prospectus. Copies of the final prospectus supplement and the accompanying prospectus relating to each offering may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of these documents may be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] and [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected]; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities referred to in this press release, nor shall there be any sale of any such securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, Revolution Medicines, APR 17, 2026, View Source [SID1234664474])

On April 17, 2026 Precision Biologics, Inc. reported a new target in Acute Myeloid Leukemia (AML) for CAR-NK therapy. Recent data for several human AML subtypes expressing truncated core 1 O-glycans will be presented in a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting on April 19th, 2026, in San Diego, CA, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster title: NEO-201-recognized truncated Core 1 O-glycans represent a new target for CAR-NK therapy in AML

Presentation of the poster will be made in person on the following date and location:

Sunday, April 19th, 2:00pm – 5:00pm PT

San Diego Convention Center, San Diego, CA, USA

Exhibit Hall

Session Category: Immunology

Session Title: Alternative Cell Type and in Situ Cell Therapies

Location: Poster Section 7

Poster Board Number: 7

Poster Number: 133

Abstract Number: 7933 (published in Cancer Research: View Source)

BACKGROUND:

Acute myeloid leukemia (AML) continues to have poor long-term outcomes, particularly in high-risk and relapsed/refractory disease. Progress in AML immunotherapy has been hindered by the scarcity of antigens selectively expressed on leukemic cells while sparing hematopoietic stem/progenitor cells (HSPCs).

Recent data to be presented for the first time at AACR (Free AACR Whitepaper), clearly identifies truncated Core 1 O-glycans recognized by NEO-201 as a novel AML-associated antigen present across multiple subtypes and largely absent from early hematopoietic progenitors. The potent antileukemic activity of NEO-201CAR NK cells in preclinical systems highlights the promise of this approach and sets the stage for advancing truncated Core 1 O-glycan-directed Cellular therapies into translational and clinical development.

"What was surprising to us was this novel target originally was discovered in solid tumors not healthy tissue, but its expression is also found in hematologic cancers. This provides the basis of targeting this specific glycan when developing cellular therapies for the treatment of refractory leukemias" said Dr. Philip M. Arlen, of Precision Biologics, Inc.

With a 5-year relative survival of only 32.9% from 2015 – 2021, it’s estimated that in the US in 2025 AML claimed about 22,000 new cases, with over 11,000 deaths. (seer.cancer.gov)

(Press release, Precision Biologics, APR 17, 2026, View Source [SID1234664490])

On April 17, 2026 Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, reported preclinical data supporting its lead ecDNA-directed therapy (ecDTx), BBI-940, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026. Boundless has identified a novel kinesin target ("Kinesin") essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940, a potentially first-in-class, oral, and selective Kinesin degrader, is currently being evaluated in the Phase 1 KOMODO-1 trial (NCT07408089) in patients with advanced or metastatic ER+/HER2- breast cancer and TNBC-LAR.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Extrachromosomal DNA is well established as a distinct enabler of chromosomal instability associated with oncogene amplification, therapeutic resistance, and poor outcomes for patients," said Chris Hassig, Ph.D., Chief Scientific Officer of Boundless Bio. "We have discovered and validated a novel kinesin target that plays a critical role in ecDNA segregation during cell division, thereby affording tumors with a high degree of genomic plasticity. Our data demonstrate that selective degradation of this target delivered potent antitumor activity in validated breast cancer models, particularly those with ecDNA. Our genetic, in vitro, in vivo, and toxicity profile of BBI-940 supports our recently initiated, first-in-human KOMODO-1 clinical trial evaluating BBI-940 in ER+/HER2- and TNBC-LAR breast cancer patients."

Details of the presentation are as follows:

Title: Selective degradation of a novel kinesin as a potential therapeutic strategy addressing high-risk extrachromosomal DNA (ecDNA) positive cancers, including breast cancer
Abstract Number: LB361
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date and Time: Tuesday April 21, 2026, 2:00 PM – 5:00 PM PT
Location: Poster Section 53
Poster Board Number: 18

Genetic and pharmacologic degradation of Kinesin caused ecDNA mis-segregation, ecDNA depletion, and reduced viability of ecDNA+ cancer cells. Selective degradation of Kinesin in a panel of tumor cell lines demonstrated sensitivity across multiple tumor types and 32% sensitivity in breast cancer cell lines, including those positive for ecDNA and FGFR1 gain. This molecularly defined subgroup for Kinesin degradation was further validated in vivo with demonstrated monotherapy tumor regressions in an ecDNA+ TNBC-LAR model, and significant antitumor activity as monotherapy and combination in an ecDNA+/FGFR1+ ER+ breast cancer model.

About BBI-940
Our lead ecDTx, BBI-940, is a novel, oral, and selective kinesin degrader being evaluated in the ongoing, first-in-human Phase 1 KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology) clinical trial (NCT07408089) in patients with advanced or metastatic estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer or triple-negative breast cancer of the luminal androgen receptor subtype (TNBC-LAR). BBI-940 targets a specific kinesin protein, "Kinesin", essential for ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940 is designed to exploit the heightened dependence of ecDNA-positive tumors on mitotic machinery by degrading Kinesin to induce mitotic catastrophe and cell death.

(Press release, Boundless Bio, APR 17, 2026, View Source [SID1234664506])

On April 17, 2026 Soley Therapeutics, a biotechnology company advancing novel therapeutics informed by integrated cell stress biology, reported the presentation of new preclinical data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 highlighting the anti-tumor activity of STX-6398, a first-in-class, oral small-molecule modulator of cytoskeleton-associated protein 2 (CKAP2) pathway. CKAP2 is an intrinsically disordered protein that has been historically considered undruggable and is central to malignant progression.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"STX-6398 is one of several potential first-in-class candidates rapidly found using our discovery platform," said Yerem Yeghiazarians, M.D., Co-Founder and Chief Executive Officer of Soley. "CKAP2 is implicated in multiple aspects of malignant progression, and its role across tumor types makes it an attractive target for therapeutic intervention. The preclinical profile of STX-6398, including biomarker-linked activity, oral dosing, and in vivo tolerability, supports continued evaluation as a potential therapeutic approach in CKAP2-expressing cancers."

Preclinical studies of STX-6398 demonstrate selective anti-tumor activity. In a 300-tumor cell line panel, sensitivity to STX-6398 correlated with CKAP2 protein abundance across cancer types, supporting a biomarker-linked therapeutic approach in both hematologic and solid tumors. Mechanistic studies showed that STX-6398 modulates CKAP2-associated pathways, including focal adhesion kinase (FAK) signaling, resulting in reduced cell migration, disruption of microtubule dynamics, and induction of cell cycle arrest. Additional studies demonstrated inhibition of angiogenesis and maintenance of activity under hypoxic conditions.

In vivo, oral administration of STX-6398 demonstrated significant anti-tumor activity across multiple xenograft models, including lung and colon cancer, with dose-dependent tumor growth inhibition and regression. The compound was well tolerated in efficacy studies and demonstrated a favorable profile in preclinical safety assessments.

The poster presented at AACR (Free AACR Whitepaper) 2026 titled "CKAP2 Modulation With A Novel Small Molecule Results In Excellent In Vitro And In Vivo Anti-Tumor Activity" is available in the Publications section of the Company’s website at View Source

The poster titled "CKAP2 Modulation With a Novel Small Molecule Results in Excellent In Vitro and In Vivo Anti-Tumor Activity" will be presented at AACR (Free AACR Whitepaper) 2026 on April 20 from 2:00 PM to 5:00 PM PDT in Poster Section 15, Poster Number 3043.

(Press release, Soley Therapeutics, APR 17, 2026, View Source [SID1234664475])